Cao Dong-yan, Shen Keng, Yang Jia-xin, Guan Jian
Department of Obstetrics and Gynecoloy, Peking Union Medical College Hospital, Peking Union Medical College and China Academy of Medical Science, Beijing 100730, China.
Zhonghua Yi Xue Za Zhi. 2007 Jul 3;87(25):1738-41.
To study the expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer (EOC) and its relationship to drug resistance and prognosis.
Immunohistochemical method was used to study the expression of MRP, GST-pi, Topo IIalpha and COX-2 in 60 cases of epithelial ovarian cancer who were treated in PUMC Hospital from 2000 to 2004. The mean age of all patients was 51.2 years old. The histological types were 35 cases of serous adenocarcinoma, 2 cases of mucinous adenocarcinoma, 11 cases of clear cell carcinoma, 4 cases of transitional cell carcinoma and 8 cases of endometrioid carcinoma. Statistical analysis was done to determine its relationships to drug resistance and prognosis.
The positive expression rate of MRP, GST-pi, Topo IIalpha and COX-2 in EOC was 26.7%, 93.3%, 61.7% and 78.3% respectively. The positive expression rate of MRP was significantly higher in clear cell carcinoma than that in non-clear cell carcinoma (54.5% vs 20.4%, P < 0.05); The expression of Topo IIalpha in advanced stage of EOC was significantly lower than that in early stage cases (56.6% vs 78.6%, P < 0.05). Positive expression of MRP, negative expression of Topo IIalpha, strong positive expression of GST-pi and COX-2 were seen as four risk factors for recurrence, drug-resistance and poor prognosis. More cases of recurrent group and drug-resistant group had 2 or more risk factors. The three-year survival rate of patients with 2 or more risk factors and patients with less than 2 risk factor are 69.9% and 91.7% respectively (P > 0.05).
There are moderate or high expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer. Having 2 or more risk factors may be seen as a vital indicator to predict drug-resistance and recurrence in patients of epithelial ovarian cancer.
研究多药耐药相关蛋白（MRP）、谷胱甘肽S转移酶π（GST-pi）、拓扑异构酶Ⅱα（TopoⅡα）和环氧合酶-2（COX-2）在上皮性卵巢癌（EOC）中的表达及其与耐药性和预后的关系。
采用免疫组化方法研究2000年至2004年在协和医院接受治疗的60例上皮性卵巢癌患者中MRP、GST-pi、TopoⅡα和COX-2的表达。所有患者的平均年龄为51.2岁。组织学类型为浆液性腺癌35例、黏液性腺癌2例、透明细胞癌11例、移行细胞癌4例和子宫内膜样癌8例。进行统计学分析以确定其与耐药性和预后的关系。
EOC中MRP、GST-pi、TopoⅡα和COX-2的阳性表达率分别为26.7%、93.3%、61.7%和78.3%。透明细胞癌中MRP的阳性表达率显著高于非透明细胞癌（54.5%对20.4%，P<0.05）；EOC晚期TopoⅡα的表达显著低于早期病例（56.6%对78.6%，P<0.05）。MRP阳性表达、TopoⅡα阴性表达、GST-pi和COX-2强阳性表达被视为复发、耐药和预后不良的四个危险因素。复发组和耐药组中更多病例有2个或更多危险因素。有2个或更多危险因素的患者和少于2个危险因素的患者的三年生存率分别为69.9%和91.7%（P>0.05）。
上皮性卵巢癌中存在MRP、GST-pi、TopoⅡα和COX-2的中度或高度表达。有2个或更多危险因素可被视为预测上皮性卵巢癌患者耐药性和复发的重要指标。
Zotero 插件